1.91 ML tezepelumab-ekko 110 MG/ML Injection
- RxCUI
- 2587794
- RxNorm name
- 1.91 ML tezepelumab-ekko 110 MG/ML Injection
- Display name
- 1.91 ML tezepelumab-ekko 110 MG/ML Injection
- Full name
- 1.91 ML tezepelumab-ekko 110 MG/ML Injection
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:00
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761224 | Tezspire | tezepelumab-ekko | 351(a) | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TEZSPIRE | TEZEPELUMAB-EKKO | Amgen Inc | 60f0aa03-ad25-4d48-80ce-7fcfa76f325f | 2025-10-17 | Warnings, Adverse reactions | 2587794 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 60f0aa03-ad25-4d48-80ce-7fcfa76f325f | 1.91 ML tezepelumab-ekko 110 MG/ML Injection | SCD | 15 | These highlights do not include all the information needed to use TEZSPIRE safely and effectively. See full prescribing information for TEZSPIRE. TEZSPIRE ® (tezepelumab-ekko) injection, for subcutaneous use Initial U.S. Approval: 2021 | 20251017 |
| 60f0aa03-ad25-4d48-80ce-7fcfa76f325f | tezepelumab-ekko 210 MG per 1.91 ML Injection | SY | 15 | These highlights do not include all the information needed to use TEZSPIRE safely and effectively. See full prescribing information for TEZSPIRE. TEZSPIRE ® (tezepelumab-ekko) injection, for subcutaneous use Initial U.S. Approval: 2021 | 20251017 |
| 60f0aa03-ad25-4d48-80ce-7fcfa76f325f | tezepelumab-ekko 210 MG in 1.91 ML Injection | PSN | 15 | These highlights do not include all the information needed to use TEZSPIRE safely and effectively. See full prescribing information for TEZSPIRE. TEZSPIRE ® (tezepelumab-ekko) injection, for subcutaneous use Initial U.S. Approval: 2021 | 20251017 |